Revolution Medicines (RVMD) Competitors $36.47 +0.75 (+2.10%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RVMD vs. ONC, BNTX, TEVA, ITCI, SMMT, GMAB, RDY, MRNA, VTRS, and QGENShould you be buying Revolution Medicines stock or one of its competitors? The main competitors of Revolution Medicines include Beigene (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Viatris (VTRS), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry. Revolution Medicines vs. Beigene BioNTech Teva Pharmaceutical Industries Intra-Cellular Therapies Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Moderna Viatris Qiagen Beigene (NASDAQ:ONC) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, community ranking, media sentiment and valuation. Do institutionals and insiders hold more shares of ONC or RVMD? 48.5% of Beigene shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 7.4% of Beigene shares are held by company insiders. Comparatively, 8.0% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, ONC or RVMD? Beigene has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500. Does the media prefer ONC or RVMD? In the previous week, Beigene had 3 more articles in the media than Revolution Medicines. MarketBeat recorded 13 mentions for Beigene and 10 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.03 beat Beigene's score of 0.54 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beigene 0 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in ONC or RVMD? Revolution Medicines received 92 more outperform votes than Beigene when rated by MarketBeat users. Likewise, 76.98% of users gave Revolution Medicines an outperform vote while only 62.50% of users gave Beigene an outperform vote. CompanyUnderperformOutperformBeigeneOutperform Votes562.50% Underperform Votes337.50% Revolution MedicinesOutperform Votes9776.98% Underperform Votes2923.02% Which has better valuation & earnings, ONC or RVMD? Revolution Medicines has lower revenue, but higher earnings than Beigene. Beigene is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeigene$3.81B6.29-$881.71M-$6.14-39.54Revolution Medicines$742K9,137.80-$436.37M-$3.57-10.22 Is ONC or RVMD more profitable? Revolution Medicines has a net margin of 0.00% compared to Beigene's net margin of -25.94%. Beigene's return on equity of -25.12% beat Revolution Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Beigene-25.94% -25.12% -14.95% Revolution Medicines N/A -33.67%-30.08% Do analysts prefer ONC or RVMD? Beigene currently has a consensus target price of $316.67, suggesting a potential upside of 30.45%. Revolution Medicines has a consensus target price of $66.67, suggesting a potential upside of 82.80%. Given Revolution Medicines' higher probable upside, analysts plainly believe Revolution Medicines is more favorable than Beigene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beigene 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Revolution Medicines 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryRevolution Medicines beats Beigene on 13 of the 17 factors compared between the two stocks. Remove Ads Get Revolution Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RVMD vs. The Competition Export to ExcelMetricRevolution MedicinesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.78B$2.90B$5.35B$7.58BDividend YieldN/A1.91%5.11%4.33%P/E Ratio-10.1630.3721.6517.78Price / Sales9,137.80438.12376.3294.47Price / CashN/A168.6838.1534.64Price / Book3.293.456.443.99Net Income-$436.37M-$72.06M$3.20B$247.24M7 Day Performance16.15%4.36%6.67%5.84%1 Month Performance-6.77%-17.35%-6.27%-5.78%1 Year Performance1.11%-31.05%8.56%-1.99% Revolution Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RVMDRevolution Medicines3.812 of 5 stars$36.47+2.1%$66.67+82.8%-1.0%$6.78B$742,000.00-10.16250Positive NewsGap UpONCBeigene2.257 of 5 stars$220.54-7.5%$310.40+40.7%N/A$21.76B$3.81B-26.7610,600Gap DownBNTXBioNTech2.5235 of 5 stars$86.82-1.4%$143.44+65.2%+11.6%$20.83B$2.75B-41.343,080Positive NewsGap UpTEVATeva Pharmaceutical Industries2.9882 of 5 stars$13.91+0.8%$23.43+68.5%+0.9%$15.77B$16.54B-9.5936,800Options VolumePositive NewsITCIIntra-Cellular Therapies3.4982 of 5 stars$131.87flat$106.23-19.4%N/A$14.05B$680.50M-151.57560Analyst ForecastPositive NewsSMMTSummit Therapeutics2.6154 of 5 stars$17.32-0.2%$35.40+104.4%+534.1%$12.78B$700,000.00-61.85110Gap UpGMABGenmab A/S4.2241 of 5 stars$18.19-1.1%$41.33+127.2%-35.7%$12.04B$21.53B10.451,660Short Interest ↓Gap DownHigh Trading VolumeRDYDr. Reddy's Laboratories3.0786 of 5 stars$12.59+1.8%$17.00+35.1%-7.5%$10.51B$311.31B20.0424,800Positive NewsHigh Trading VolumeMRNAModerna4.2556 of 5 stars$25.64+2.1%$59.00+130.1%-75.1%$9.91B$3.20B-2.763,900Positive NewsGap UpVTRSViatris2.7984 of 5 stars$7.61-0.1%$10.50+38.0%-33.5%$9.08B$14.74B-10.2837,000High Trading VolumeQGENQiagen3.496 of 5 stars$40.33+5.4%$47.71+18.3%+7.5%$8.96B$1.98B112.296,030High Trading Volume Remove Ads Related Companies and Tools Related Companies ONC Alternatives BNTX Alternatives TEVA Alternatives ITCI Alternatives SMMT Alternatives GMAB Alternatives RDY Alternatives MRNA Alternatives VTRS Alternatives QGEN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RVMD) was last updated on 4/14/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump’s betrayal exposed Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revolution Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
